A20 lymphoma B cells were injected subcutaneously (S.C.; 3 × 105 per mouse) into the left flank of syngeneic female BALB/c mice (6–8 weeks of age). At day 7 after tumour implantation, mice bearing tumours of similar sizes were randomly assigned to treatment with 6 Gy of total body irradiation (TBI), and 4–6 h later with infusion of CD4 CTLs primed by LMP1-A20 cells or naive CD4 cells as control (0.4 × 106 each; both containing ~6% CD4+ Tregs). For PD-1 blockade, animals treated with or without the CD4 CTLs as described above were injected intraperitoneally (I.P.; 100 μg per mouse) with PD-1 blocking antibody (clone 29F.1A12) or isotype control antibody (clone 2A3) (both from BioXCell) at days 15 and 19 post-tumour challenge. Tumours were measured unblinded with a caliper every two days, and the tumour volume was calculated using the following formula: (A × B2)/2 (A as the largest and B the smallest diameter of the tumour). Animals were euthanized when their tumours reached 20 mm in any direction or when they exhibited signs of impaired health.
Pd 1 blocking antibody clone 29f 1a12
Manufactured by BioXCell
Sourced in United States
The PD-1 blocking antibody (clone 29F.1A12) is a lab equipment product designed to block the programmed cell death-1 (PD-1) receptor. This antibody can be used in research applications to study the role of PD-1 in various biological processes.
Automatically generated - may contain errors
Lab products found in correlation
3 protocols using pd 1 blocking antibody clone 29f 1a12
1
Combination Therapy for A20 Lymphoma
2
PD-1 Blockade in Kras Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
PD-1 blocking antibody (clone 29F.1A12) and isotype control (clone 2A3) were purchased from BioXcell (West Lebanon, NH, USA). Antibodies were administrated by intraperitoneal injection (200 µg in PBS per dose) in Kras and Il-17c−/−/Kras mice three times a week for four weeks.
3
Combination Therapy for A20 Lymphoma
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
A20 lymphoma B cells were injected subcutaneously (S.C.; 3 × 105 per mouse) into the left flank of syngeneic female BALB/c mice (6–8 weeks of age). At day 7 after tumour implantation, mice bearing tumours of similar sizes were randomly assigned to treatment with 6 Gy of total body irradiation (TBI), and 4–6 h later with infusion of CD4 CTLs primed by LMP1-A20 cells or naive CD4 cells as control (0.4 × 106 each; both containing ~6% CD4+ Tregs). For PD-1 blockade, animals treated with or without the CD4 CTLs as described above were injected intraperitoneally (I.P.; 100 μg per mouse) with PD-1 blocking antibody (clone 29F.1A12) or isotype control antibody (clone 2A3) (both from BioXCell) at days 15 and 19 post-tumour challenge. Tumours were measured unblinded with a caliper every two days, and the tumour volume was calculated using the following formula: (A × B2)/2 (A as the largest and B the smallest diameter of the tumour). Animals were euthanized when their tumours reached 20 mm in any direction or when they exhibited signs of impaired health.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!